Three men over age 50 years, three different lesions: which would concern you?
Two of these lesions were identified during routine physical exams, one was the presenting symptom. All benign? All malignant? Or some combination. Click through the slides to find out.
Lebrikizumab Demonstrates Efficacy, Safety in Patients With Skin of Color With AD
June 11th 2025RAD 2025. Lebrikizumab improved skin clearance, itch, and pigmentation in patients with skin of color and atopic dermatitis, with strong safety data through 24 weeks, according to late-breaking data.